c-MYC is an aggregation-prone, amyloidogenic protein

This study reveals that c-MYC is an aggregation-prone, amyloidogenic protein whose spontaneous formation of amyloid oligomers induces transcription-independent apoptosis, suggesting a built-in failsafe mechanism that contributes to its paradoxical tumor-suppressing activity.

The Gist

The Story of the "Double-Agent" Protein

Imagine your body is a bustling city, and c-MYC is a famous, high-powered mayor. This mayor has two very different jobs:

1. The Builder: When things are running smoothly, c-MYC helps the city grow, repair itself, and keep the lights on (this is how it helps cells divide and function).
2. The Self-Destruct Button: However, if the mayor gets too powerful, starts acting crazy, or if the city is under attack, c-MYC has a secret fail-safe. It can suddenly decide to shut the whole city down to prevent a disaster (this is called apoptosis, or programmed cell death).

For years, scientists were confused by this "paradox." They knew c-MYC could cause cancer (by building too much) but also kill cancer cells (by shutting them down). They assumed the "shut down" button only worked because c-MYC was sending out orders to the city's computer system (transcription).

This paper reveals a shocking new secret: c-MYC has a physical, "glitchy" side that acts as a backup kill switch, completely independent of its computer orders.

---

The Big Discovery: c-MYC Turns into "Jelly"

The researchers discovered that c-MYC is a bit unstable. Under stress (like heat shock or high pressure), c-MYC doesn't just stay as a neat, individual protein. Instead, it starts to stick to itself, clumping together into sticky, tangled balls.

• The Analogy: Think of c-MYC as a piece of cooked spaghetti. Normally, it's a long, flexible noodle. But if you heat it up or let it sit too long, it starts to stick to other noodles, forming a giant, hard-to-digest clump.
• The Science: These clumps are called amyloids. You might know amyloids from diseases like Alzheimer's, where brain proteins clump up and cause damage. The surprise here is that c-MYC, a protein usually associated with cancer, also does this.

The "Safety Net" Partner: MAX

c-MYC usually works with a partner named MAX.

• The Analogy: Imagine c-MYC is a wild, energetic dog that loves to chew things up (form amyloid clumps). MAX is a calm, gentle dog that loves to sit still. When they are leashed together (dimerized), MAX keeps c-MYC calm and prevents it from chewing up the furniture.
• The Discovery: In healthy cells, there is plenty of MAX to keep c-MYC in check. But in cancer cells, c-MYC goes into overdrive, and there isn't enough MAX to leash it all. Without MAX holding it back, c-MYC starts clumping up on its own.

The "Glitch" Regions

The researchers zoomed in on the c-MYC protein to find exactly where it starts to clump. They found two specific "sticky spots" (short sections of the protein) that act like velcro.

• The Analogy: If c-MYC is a long coat, these two spots are like the velcro patches on the sleeves. If you cut those patches off, the coat stops sticking to itself.
• The Result: When the researchers removed these sticky spots, c-MYC stopped forming clumps and, crucially, stopped killing the cancer cells. This proves that the clumping itself is what triggers the cell's self-destruction.

Why This Matters: The "Built-in Fail-Safe"

This discovery changes how we understand cancer and even Alzheimer's.

1. The Cancer Fail-Safe: The body has a brilliant safety mechanism. If a cell becomes a cancer monster and c-MYC goes crazy, the protein physically clumps up. This clumping acts as a "Self-Destruct" button that kills the cancer cell, even if the cell's computer (DNA) is broken and can't send normal orders. It's nature's way of saying, "If you can't control the mayor, we'll just lock the city down."
2. The Alzheimer's Connection: The researchers also found these c-MYC clumps in the brains of people with Alzheimer's disease. This suggests that c-MYC might be contributing to brain cell death in neurodegenerative diseases, not just cancer.

Summary in One Sentence

The paper reveals that the cancer-causing protein c-MYC has a hidden "glitch" where it physically clumps together like sticky spaghetti; this clumping acts as a built-in emergency brake that kills cancer cells, a mechanism that works even when the cell's normal control systems have failed.

Technical Summary

1. Problem Statement

The transcription factor c-MYC is a well-established oncogenic driver but also possesses a paradoxical intrinsic tumor-suppressor activity, often inducing apoptosis under stress or when overexpressed. Traditionally, this apoptosis has been attributed solely to c-MYC's transcriptional activity. However, the molecular mechanism behind this "paradox of c-MYC" remains incompletely understood. Furthermore, protein misfolding and aggregation (amyloidogenesis) are typically associated with neurodegenerative diseases (e.g., Alzheimer's), not cancer. The authors investigate whether c-MYC itself possesses intrinsic amyloidogenic properties that could explain its tumor-suppressive function and its presence in neurodegenerative contexts.

2. Methodology

The study employed a multi-faceted approach combining cell biology, biochemistry, structural biology, and in vivo tissue analysis:

• Cellular Stress Models: HeLa cells were subjected to heat shock (HS) to induce proteotoxic stress. Soluble and detergent-insoluble fractions were separated to detect aggregation.
• Amyloid Detection Tools:
  • Congo Red (CR): Used to inhibit amyloidogenesis and stain aggregates.
  • Thioflavin T (ThT): Used to detect amyloid fibrils via fluorescence in in vitro assays.
  • A11 Antibody: A conformation-specific antibody used to detect soluble prefibrillar amyloid oligomers (AOs) independent of primary sequence.
  • Proximity Ligation Assay (PLA): Used in situ to detect c-MYC oligomerization within cells and tissues.
  • Transmission Electron Microscopy (TEM): Used to visualize protofibrils and fibrils.
• In Vitro Reconstitution: Recombinant c-MYC, MAX (its obligate dimerization partner), and other transcription factors were purified and incubated to observe spontaneous fibrillation and oligomerization.
• Peptide Library Screening: A synthetic library of 19-mer non-overlapping peptides covering the human c-MYC sequence was screened to identify specific amyloidogenic regions.
• Alanine Scan: Systematic mutation of amino acids within identified regions to pinpoint residues critical for aggregation.
• Functional Assays:
  • Apoptosis Detection: Flow cytometry for cleaved Caspase-3 in NIH-3T3 cells overexpressing wild-type c-MYC, transcription-deficient mutants (lacking DNA-binding/MAX-dimerizing domains), and deletion mutants of amyloidogenic regions.
  • Transcriptional Activity: Dual-luciferase reporter assays (SEAP/GLuc) to measure transcriptional output.
• Tissue Analysis: Immunohistochemistry and PLA were performed on human cancer tissues (liver, prostate, melanoma) and Alzheimer's disease (AD) brain tissues.

3. Key Contributions

• Discovery of c-MYC Amyloidogenicity: The paper establishes that c-MYC is intrinsically aggregation-prone and forms amyloid-like structures, a property not shared by its obligate partner MAX.
• Identification of Amyloidogenic Regions: Two specific intrinsically disordered regions (IDRs) within c-MYC (amino acids 20–39 and 210–228) were identified as the primary drivers of amyloidogenesis.
• Mechanism of MAX Suppression: The study demonstrates that dimerization with MAX suppresses c-MYC amyloidogenesis, providing a structural basis for how physiological levels of c-MYC are kept non-toxic.
• Transcription-Independent Apoptosis: The authors prove that c-MYC-induced apoptosis can occur via an amyloid-mediated, transcription-independent mechanism.
• Pathological Relevance: The detection of c-MYC amyloid oligomers in both human cancer tissues and Alzheimer's disease brains links c-MYC aggregation to both oncology and neurodegeneration.

4. Key Results

• Stress-Induced Aggregation: Upon heat shock, c-MYC transitions from a soluble state to detergent-insoluble aggregates in HeLa cells, whereas MAX and major chaperones (HSP90, HSP70) do not aggregate. This aggregation is blocked by Congo Red.
• Endogenous Oligomers: Even without heat shock, soluble c-MYC oligomers (detected by A11 antibody) are present in human cancer tissues and Alzheimer's brains. These oligomers are cytoplasmic, suggesting they are transcriptionally incompetent.
• In Vitro Spontaneous Fibrillation: Purified recombinant c-MYC spontaneously forms ThT-positive fibrils and A11-positive soluble oligomers. In contrast, MAX, USF1, OCT4, and HSF1 do not form amyloids.
• MAX Antagonism: Recombinant c-MYC/MAX heterodimers fail to form amyloid fibrils. Disrupting the MYC/MAX dimer in cells (using 10058-F4) increases A11-positive c-MYC oligomers.
• Peptide Mapping: Screening of a peptide library identified two amyloidogenic fragments: P2 (aa 20–38) and P12 (aa 210–228). Both are in IDRs. Alanine scanning revealed that most residues in these regions contribute to amyloid formation.
• Apoptosis Mechanism:
  • A transcription-deficient c-MYC mutant (lacking the C-terminal DNA-binding and MAX-dimerizing domains) still induces apoptosis.
  • Deleting the two amyloidogenic regions (P2 and P12) from this mutant significantly reduces its ability to induce apoptosis, even though residual transcriptional activity remains.
  • This confirms that c-MYC amyloidogenesis drives cytotoxicity largely independently of transcription.

5. Significance

• Resolving the "Paradox of c-MYC": The study proposes a "built-in failsafe mechanism." Under normal conditions, low c-MYC levels and dimerization with MAX prevent aggregation. However, in cancer where c-MYC is overexpressed and MAX levels may not correlate, the excess c-MYC aggregates. This aggregation triggers apoptosis, acting as a tumor-suppressive brake against uncontrolled oncogenic potential.
• Novel Therapeutic Targets: The identification of specific amyloidogenic regions (P2 and P12) offers new targets for therapeutic intervention. Stabilizing these regions or promoting MAX dimerization could potentially modulate c-MYC toxicity.
• Linking Cancer and Neurodegeneration: The presence of c-MYC amyloids in Alzheimer's brains suggests a potential mechanistic link between c-MYC dysregulation and neurodegeneration, expanding the scope of c-MYC biology beyond cancer.
• Redefining Protein Aggregation: The findings challenge the notion that amyloidogenesis is exclusive to neurodegenerative diseases, highlighting its role as a regulatory or destructive mechanism in cancer biology.

In conclusion, this paper fundamentally recharacterizes c-MYC as an aggregation-prone protein whose amyloid state serves as a critical, transcription-independent tumor-suppressive mechanism, while also implicating it in the pathology of Alzheimer's disease.